BioCentury | Nov 18, 2016
Company News

Thar, Gruenenthal deal

...drugs into oral candidates. Grünenthal plans to conduct Phase III testing of Thar's lead program, T121...
...formulation of zoledronic acid has Orphan Drug designation from FDA in the indication. Grünenthal said T121...
...inquiries. Thar Pharmaceuticals Inc. , Pittsburgh, Pa. Grünenthal Group , Aachen, Germany Business: Neurology Jaime De Leon T121 Gruenenthal...
BioCentury | Nov 17, 2016
Company News

Gruenenthal buys oral formulation company Thar

...drugs into oral candidates. Gruenenthal plans to conduct Phase III testing of Thar's lead program, T121...
...formulation of zoledronic acid has Orphan Drug designation from FDA in the indication. Gruenenthal said T121...
...CRPS. In August, Thar filed to raise up to $50 million in an IPO. Jaime De Leon T121 Gruenenthal...
Items per page:
1 - 2 of 2